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Abstract
MicroRNAs have emerged as ubiquitous post-transcriptional regulators that coordinate
many fundamental processes within cells, including those commonly linked to cancer when
dysregulated. Profiling microRNAs across stages of cancer progression provides focus as
to which microRNAs are key players in cancer development and are therefore important to
manipulate with interventions to delay cancer onset and progression. Calorie restriction is
one of the most effective preventive interventions across many types of cancer, although
its effects on microRNAs have not been well characterized. We used the dimethylbenz[a]-
anthracene-induced model of luminal mammary cancer in Sprague Dawley rats to elucidate
which microRNAs are linked to progression in this type of cancer and, subsequently, to
study how calorie restriction affects such microRNAs. We identified eight microRNAs (miR-
10a, miR-10b, miR-21, miR-124, miR-125b, miR-126, miR-145 and miR-200a) to be associ-
ated with DMBA-induced mammary tumor progression. Calorie restriction, which greatly
increased tumor-free survival and decreased the overall size of tumors that did develop, sig-
nificantly decreased the expression of one microRNA, miR-200a, which was positively
associated with tumor progression. We further showed that inhibition of miR-200a function,
mimicking the effect of calorie restriction on this microRNA, inhibited proliferation in both rat
(LA7) and human (MCF7) luminal mammary cancer cell lines. These findings present, for
the first time, a stage-specific profile of microRNAs in a rodent model of luminal mammary
cancer. Furthermore, we have identified the regulation of miR-200a, a microRNA that is
positively associated with progression in this model, as a possible mechanism contributing
to the anticancer effects of calorie restriction.
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Introduction
Calorie restriction (CR), a dietary regimen in which subjects receive a nutritionally replete but
reduced energy diet (typically ~30% reduction in total energy intake) is arguably the most
potent and broadly acting dietary intervention for preventing or inhibiting cancer in experi-
mental tumor models, including rodent models of several intrinsic subtypes of breast cancer
[1]. Moreover, CR is increasingly being applied to human cancer as a preventive strategy or in
cancer patients as a sensitizing strategy prior to chemotherapeutic or radiation therapy regi-
mens [2,3,4]. While the beneficial effects of CR are well established, the mechanisms through
which CR affects cancer are poorly understood, hampering efforts to translate CR to the pre-
vention and control of human cancer [5,6].
A broad spectrum of genes are modulated by CR, suggesting that this dietary intervention
may modulate one or more master regulators of gene expression [7]. One such regulation sys-
tem functions through microRNAs (miRNAs), which are small (21–25 nucleotide) non-pro-
tein coding RNAs known to broadly regulate the expression and/or translation of mRNAs [8].
Breast cancer has been a major focus of miRNA research over the past decade, leading to the
elucidation of the oncogenic or tumor suppressive functions of miRNAs via regulation of target
mRNAs involved in several breast cancer hallmarks, including tumor growth, apoptosis, inva-
sion, and inflammation [9,10]. Advances in miRNA profiling have aided in the discovery of
these key cancer regulators and are facilitating the definition of miRNA expression patterns
across different tissue types [11]. Profiling of human breast samples has identified differentially
expressed miRNAs in many important comparisons, including between normal and cancerous
tissue, during the progression stages leading up to invasive disease, between tumor subtypes,
and between cases with varying clinical outcomes [11,12,13,14,15,16]. However, no profiling to
date has focused on the development and progression of breast cancer within an individual
subtype, which would provide a more accurate assessment of miRNA signatures considering
there are significant subtype-specific differences in miRNA expression. Furthermore, the
potential impact of dietary energy balance modulation, such as CR, on progression-related
miRNA profiles has not yet been characterized.
Here, we used the dimethylbenz[a]-anthracene (DMBA)-induced mammary cancer model
in Sprague Dawley rats and global miRNA expression array analysis to profile miRNA expres-
sion across multiple stages of luminal mammary tumor development and progression. The
DMBA rat model was selected since DMBA induces preneoplastic lesions, including intraduc-
tal proliferation (IDP) and mammary intraepithelial neoplasias (MIN, equivalent to ductal car-
cinoma in situ in humans) that progress to ER-positive invasive ductal carcinomas (IDC) in
rats that are similar to the most prevalent subtype of breast cancer (luminal A) in women
[17,18,19,20]. We also tested the hypothesis that CR inhibits mammary tumor development
and/or progression in association with alterations in one or more key miRNAs identified in
our profiling studies. We identified, for the first time to our knowledge, a panel of miRNAs
associated with luminal mammary tumor progression. Moreover, we found that CR strongly
suppresses DMBA-induced mammary tumor development, and that one of these progression-
associated miRNAs, miR-200a, is highly responsive to CR and may be an important contribu-
tor to the anticancer effects of CR.
Materials and Methods
Rats, diets, and study design
All rats were housed in the Animal Resource Center at the University of Texas at Austin. All
animal studies and procedures were approved and monitored by the Institutional Animal Care
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and Use Committee at the University of Texas. Control rats were monitored at least once per
week, while CR rats were monitored daily and given nestlets and huts to alleviate distress. No
rats died prior to study endpoints.
Rats were purchased from Charles River Laboratories, Wilmington, MA. Upon arrival, 208
5-week old female Sprague Dawley rats, housed 3 per cage, received a modified AIN-76A diet
(control, consumed ad libitum; catalog # D12450B, Research Diets, Inc., New Brunswick, NJ)
for two weeks. After this acclimation period, rats were randomly assigned to receive a single
dose via gavage of either a) the carcinogen dimethylbenz(a)anthracene (DMBA) (65mg/kg, dis-
solved in sesame oil [30mg/mL], n = 155) or b) sesame oil alone (vehicle, equivalent volume,
n = 53). Rats were further randomized into one of two substudies: a) a time course study
(DMBA, n = 95; vehicle, n = 13) or b) a tumor-free survival study including dietary interven-
tion (DMBA, n = 60; vehicle, n = 40).
Time course study. Beginning six weeks after DMBA administration, and continuing
until study endpoint (16 weeks post-DMBA administration), rats were palpated every two
weeks and euthanized when tumor was first discovered for mammary gland collection. Vehi-
cle-treated rats had no tumor development and were euthanized 16 weeks after DMBA treat-
ment (study endpoint). All rats were fasted for 12 hours, anesthetized with CO2, and then
euthanized by cervical dislocation.
Tumor-free survival study. Rats assigned to the survival substudy were singly housed and
randomized to receive either a) control diet, (described above; DMBA, n = 20; vehicle, n = 20)
or b) a 30% calorie restriction diet (CR; consumed as daily aliquot; DMBA, n = 40; vehicle,
n = 20; catalog # D03020702, Research Diets, Inc). The CR diet is a modified AIN-76A semi-
purified diet that is calculated to provide 30% less total calories while maintaining 100% of all
vitamins, minerals, fatty acids, and amino acids relative to the control group. Mammary fat
pads were palpated twice weekly, and rats were euthanized as previously described if one of
two criteria were met: a tumor reached 1.2 cm in any direction or study endpoint was reached
(12 weeks post-DMBA administration). The number of rats in the CR diet group was higher
than in the control diet group to ensure that, in the event CR inhibited tumor development, we
would collect sufficient tumor material from rats on the CR diet for subsequent analyses.
Tissue processing and histopathologic analysis
Mammary fat pad and tumor tissue was excised, split longitudinally, and either snap-frozen in
liquid nitrogen and stored at -80°C or fixed in 10% neutral-buffered formalin for 24 hours,
transferred to 70% ethanol for 24 hours, and embedded in paraffin. Formalin-fixed, paraffin-
embedded (FFPE) mammary fat pads were cut into 4-μm sections, placed on slides, deparaffi-
nized in xylene, and rehydrated. Slides were stained with hematoxylin and eosin (H&E) and
histologically assessed (in a blinded manner) by a board-certified pathologist (P. LeBourgeois)
into one of four stages of cancer progression: normal tissue, intraductal proliferation (IDP),
mammary intraepithelial neoplasia (MIN), or invasive ductal carcinoma (IDC) [20].
MicroRNA expression analysis
RNA extraction. FFPE tissue from the time course study was microdissected in a progres-
sion stage-specific manner so that comparisons between different stages could be conducted.
Once tissue was microdissected, total RNA was isolated using RecoverAll™ Total Nucleic Acid
Isolation Kit for FFPE (Ambion, Carlsbad, CA) following manufacturer’s protocols. Total
RNA from the survival study was isolated from flash-frozen tumors using TRI Reagent1
(Sigma-Aldrich, St. Louis, MO) according to manufacturer’s instructions. RNA quantity and
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quality was measured on a Nanodrop 2000 spectrophotometer (Thermo Scientific, Waltham,
MA) and a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Time course study microRNA array and validation. Total RNA samples from cancer
stage-specific lesions (n = 2/stage) from the time course study were run on an Affymetrix Gen-
eChip miRNA 2.0 array (Affymetrix, Santa Clara, CA) at Asuragen, Inc. (Austin, TX) as previ-
ously described (Ovcharenko 2011). The following criteria were used to select miRNAs of
interest that were trending toward a relevant effect in this preliminary screen: an average fluo-
rescence that was 50% above minimal acceptable limit and at least a two-fold change in expres-
sion between any two stages.
MicroRNAs that were selected in this manner were then extensively analyzed in several
reverse transcription quantitative PCR-based (RT-qPCR) validation steps. Complementary
DNA of miRNAs for PCR-based analyses was generated using the Universal cDNA Synthesis
Kit (Exiqon, Vedbaek, Denmark). Stage I validation included all array-identified miRNAs, in
addition to some well-established breast cancer-associated miRNAs (44 miRNAs in total).
Stage I validation was done using the same RNA samples run on the array (n = 2/stage) with a
custom Pick-&-Mix microRNA PCR Panel (each probe-sample combination plated in dupli-
cate) and SYBR1 Green master mix (Exiqon) on a Mastercycler1 ep gradient S (Eppendorf,
Hamburg, Germany). The miRNAs from stage I validation identified as trending toward a
relevant effect (fold change between two stages of at least 2.0) were included in stage II valida-
tion (15 miRNAs total). Stage II validation analyzed the expression of these 15 miRNAs in 6
freshly-extracted total-RNA samples per stage by RT-qPCR using microRNA LNA™ PCR
primer sets (plated in triplicate) and SYBR1 Green master mix (Exiqon) on a ViiA™ 7 Real-
Time PCR system (Applied Biosystems, Carlsbad, CA). MicroRNA-16 was used as the refer-
ence gene for PCR-based analyses and relative expression calculations were done using the
ΔΔCt method.
Survival study RT-qPCR analyses. RNA extracted from tumors from control and CR-fed
rats was analyzed for expression of miRNAs identified in the time course study. Complemen-
tary DNA of miRNAs for these analyses was generated using the TaqMan1MicroRNA
Reverse Transcription Kit (Applied Biosystems). Individual miRNA assays were done using
TaqMan1MicroRNA Assays and TaqMan1 Universal PCR Master Mix on a ViiA™ 7 Real-
Time PCR system (Applied Biosystems). All steps of assays were done according to manufac-
turer’s protocols. MicroRNA-16 was used as the reference gene for all PCR-based analyses and
relative expression calculations were done using the ΔΔCt method.
MiR-200a inhibition and proliferation assays
Rat LA7 cells (obtained directly from ATCC, catalog #: CRL-2283), which were originally
derived from a DMBA-induced mammary tumor in a Sprague Dawley rat, and human MCF7
cells (obtained directly from ATCC, catalog #: HTB-22) were used in in vitro experiments.
MicroRNA-200a inhibition was performed using 5nM miR-200a-targeting and non-targeting
control power inhibitors (Exiqon), transfected in tandem with a synthetic miR-200a target
RenSP luciferase reporter plasmid (Switchgear Genomics, Carlsbad, CA) at a ratio of 1:5 (ng:
nL) with Dharmafect Duo transfection reagent (GE Healthcare, Pittsburgh, PA). Twenty-four
hours after transfection, cells were seeded into two separate 96-well plates, one for luciferase
readout to verify miRNA inhibition and one for proliferation analysis. Luciferase and prolifera-
tion analyses were done 24 hours after reseeding, for a total of 48 hours after miRNA inhibi-
tion. RenSP luciferase signal was analyzed using LightSwitch Assay Reagent (Switchgear
Genomics) according to manufacturer protocol. Cellular proliferation was measured using a
BrdU ELISA kit (Roche, Basel, Switzerland) following manufacturer protocol.
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Statistical analyses
Summarized data are reported as mean ± SEM, except body weight and tumor area data which
are reported as mean ± SD. Analyses and statistics of array data were done as previously
described [21]. Tumor area difference was tested using a MannWhitney U test. Survival curves
were compared using the log-rank test, and body weight was analyzed at 9 weeks on diet using
one-way ANOVA. Differences in miRNA expression and luciferase signal were assessed using
the unpaired, two-tailed Student’s t-test. Cellular proliferation analysis was done using a one-
sample t-test. Significance was determined at P< 0.05.
Results
To study the miRNA profiles across progression stages in a model of luminal mammary carci-
noma, rats were treated with the carcinogen DMBA and euthanized every two weeks between a
period of 6–16 weeks post-DMBA administration, based on when tumor was palpable. By 16-
weeks post-DMBA administration, 90% of the DMBA-treated rats had developed palpable
tumors in their abdominal mammary fat pads (MFPs), while no tumors developed in the vehi-
cle-only control rats (Fig 1A). Tumor-bearing MFPs of DMBA-treated rats were scored to
identify areas of tissue representing four distinct pathological characterizations, including nor-
mal, intraductal proliferation (IDP), mammary intraepithelial neoplasia (MIN), or invasive
Fig 1. Time course study tumor development allowed collection of mammary tissue throughout progression. (A),
Percentage of rats without palpable tumor in response to oral gavage of 65 mg/kg DMBA or vehicle-only treatment until
study endpoint 16-weeks post administration. (B), representative H&E sections of normal mammary ductal tissue,
intraductal proliferation (IDP) tissue, mammary intraepithelial neoplasia (MIN) tissue, and invasive ductal carcinoma (IDC)
tissue.
doi:10.1371/journal.pone.0159686.g001
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ductal carcinoma (IDC) (Fig 1B). Normal ducts were identified based on organized, single
layer ductal epithelium while IDP was characterized by thickening of the ductal epithelium and
the presence of nuclear atypia. MIN lesions presented highly atypical cells filling, yet confined
within, the duct and IDC consisted of highly atypical cells infiltrating past the basement mem-
brane into surrounding mammary tissue.
Tissue regions representing each of these four stages were microdissected for individual
analysis. Global miRNA expression analysis was done on each lesion grade by microarray as a
screen to identify miRNAs of interest that may be differentially expressed between progression
stages (Table 1). Forty-four miRNAs were selected from those identified to be of interest and
were tested by RT-qPCR using the same RNA samples used in the global array. This initial test
identified 15 miRNAs that were trending toward differences in expression between any two
stages. These 15 miRNAs were then subjected to more rigorous RT-qPCR testing and ulti-
mately 8 miRNAs were identified that are increasingly dysregulated from normal expression
levels as the severity of mammary lesion increases (Fig 2). The majority of these progression-
associated miRNAs, including miR-10a, miR10b, miR-124, miR-125b, miR-126, miR-145,
were increasingly downregulated with increasing lesion severity, while 2 miRNAs, miR-21 and
miR-200a, were upregulated with advancing tumor progression.
To investigate which of these progression-associated miRNAs were modulated by CR, a
second animal study was conducted involving DMBA-treated rats receiving either an ad
libitum-fed control diet or a CR diet. Rats on the CR regimen maintained a steady body
weight over the course of the study while control rats consistently gained weight, leading to a
significant difference in body weight between CR rats and their Control counterparts at 9
weeks on diet, the latest point at which 50% of rats in any group remained tumor-free
(P<0.001) (Fig 3A). There was no difference in body weight between DMBA-treated and
vehicle-treated rats within the same diet group. After 12 weeks on diet, 20% of Control rats
had not developed tumor, while 43.6% of CR rats remained tumor-free (P = 0.013) (Fig 3B).
Of the tumors that did form, those from CR rats (median = 109.4mm2) were significantly
smaller than those from the Control group (median = 250.9, P = 0.009) (Fig 3C). Taken
together these results indicate an increase in tumor-free survival and a reduction in tumor
burden with the CR diet.
The 8 miRNAs we identified to be progression-associated were assessed in tumor RNA sam-
ples from Control and CR mice, and only one, miR-200a, was found to be CR-responsive (Fig
4A). Specifically, miR-200a was downregulated by 57% in CR tumors compared to Control
tumors (P = 0.002). When miR-200a function was inhibited in vitro in both rat and human
luminal mammary cancer cell lines to mimic the effect of CR on this miRNA, cellular prolifera-
tion was significantly decreased compared to a non-targeting inhibitor control (LA7: P = 0.012,
MCF7: P = 0.037)(Fig 4B and 4C). This result indicates that miR-200a has a pro-proliferative
function in mammary cancer cells and corresponds with the finding that its expression
increases in vivo throughout progression of luminal mammary cancer.
Discussion
The investigation of miRNAs as powerful post-transcriptional regulators has proven useful in
understanding, profiling, and treating breast cancers [10]. Different subtypes of human breast
cancer are known to display distinct gene expression profiles, although profiling of miRNAs
associated with development or progression of ER-positive luminal cancers is lacking [14,22].
Here, we present for the first time a miRNA expression profile across the tumorigenesis spec-
trum, from normal to preneoplastic (IDP to MIN) and ultimately to IDC, in a well-character-
ized rat model of luminal mammary carcinoma. We identified 8 miRNAs that are associated
Stage-Specific MicroRNAs and Calorie Restriction
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hsa-miR-1 78.854 0.017 11.879 hsa-miR-152 — — 0.438 hsa-miR-432 — 2.757 —
hsa-miR-15a 0.351 3.417 — hsa-miR-155 5.417 — 2.681 hsa-miR-453 — 3.356 0.429
hsa-miR-17 0.332 2.761 2.896 hsa-miR158 — 2.799 — hsa-miR-
483-
— 2.960 —
hsa-miR-20b — — 5.829 hsa-miR160 — 2.404 — hsa-miR-484 — — 2.021
hsa-miR-21 0.459 — — hsa-miR-183 0.342 — — hsa-miR-492 — — 8.364
hsa-miR-26b — — 2.205 hsa-miR-185 7.563 — — hsa-miR-501 2.992 — —
hsa-miR-28 0.128 — — hsa-miR186 — 0.429 0.492 hsa-miR-503 3.940 — —
hsa-miR-29b 0.357 3.548 — hsa-miR-187 0.444 0.221 3.763 hsa-miR-510 — — 2.583
hsa-miR-29c 0.217 4.043 3.885 hsa-miR-188 — — 0.478 hsa-miR-
518c
3.644 0.438 3.509
hsa-miR30 — — 5.731 hsa-miR-
193a
— 3.626 — hsa-miR-
519e
— — 2.935
hsa-miR-30a — — 5.096 hsa-miR-
193b
0.236 3.484 — hsa-miR-527 — — 2.004
hsa-miR-30b — 3.027 — hsa-miR-194 — 3.219 — hsa-miR-552 0.191 — —
hsa-miR-30c 0.354 4.523 — hsa-miR-
196a
9.077 — 0.154 hsa-miR-566 — 3.757 2.595
hsa-miR-30e 0.156 — — hsa-miR-
200a
0.129 4.444 6.503 hsa-miR-571 6.166 — —
hsa-miR-31 0.383 — — hsa-miR-
200b
0.447 — — hsa-miR-574 — — 0.356
hsa-miR-34a 0.262 2.198 — hsa-miR-206 21.439 0.067 5.582 hsa-miR-575 0.309 5.327 —
hsa-miR-92b 0.029 — — hsa-miR208 0.48377 — — hsa-miR-595 — 2.260 —
hsa-miR-95 — 3.338 0.414 hsa-miR-212 — — 0.442 hsa-miR-601 — — 2.599
hsa-miR-98 — — 3.556 hsa-miR-213 0.074 — — hsa-miR-608 0.412 — —
hsa-miR102 3.890 — — hsa-miR219 — — 2.629 hsa-miR-610 6.083 0.468 —
hsa-miR-
106a
0.499 ― — hsa-miR223 3.566 3.714 — hsa-miR-611 0.008 — —
hsa-miR-
124a
— 6.951 0.345 hsa-miR246 4.717 — — hsa-miR-612 — 3.034 0.381
hsa-miR-126 — — 0.497 hsa-miR254 — — 2.170 hsa-miR-619 — 0.401 —
hsa-miR128 — — 0.206 hsa-miR258 3.530 2.374 — hsa-miR-622 — — 0.380
hsa-miR-129 5.472 — — hsa-miR-324 0.111 16.217 — hsa-miR-623 0.181 0.282 2.380
hsa-miR-
130b
5.764 — 4.818 hsa-miR-328 — — 0.053 hsa-miR-628 — 5.259 —
hsa-miR-
133a
46.673 0.007 — hsa-miR-342 — — 5.336 hsa-miR-630 3.469 0.240 —
hsa-miR-
133b
122.117 0.040 9.901 hsa-miR-362 — — 2.820 hsa-miR-633 8.840 0.104 —
hsa-miR-134 — — 0.467 hsa-miR-373 6.130 0.406 — hsa-miR-636 — — 0.172
hsa-miR-138 — 0.398 — hsa-miR-375 — 0.493 — hsa-miR-648 — 0.417 2.543
hsa-miR-139 0.135 — — hsa-miR-378 — — 3.902 hsa-miR-650 10.095 — 0.322
hsa-miR141 3.098 — 2.076 hsa-miR-382 3.147 7.132 — hsa-miR-658 4.005 0.392 —
hsa-miR-142 — — 2.480 hsa-miR-421 0.439 2.380 — hsa-miR-662 — 6.114 3.248
hsa-miR-
146a
— — 2.557 hsa-miR-425 — 2.41603 0.085
IDP, intraductal proliferation; MIN, mammary intraepithelial neoplasia; IDC, invasive ductal carcinoma. MiRNAs identified to be of interest based on a change
in expression of at least 2-fold, array readout of one group averaging above minimal acceptable limit, and all readouts within one group being above or below
average readout of its comparison group.
doi:10.1371/journal.pone.0159686.t001
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with mammary tumor progression, and found that one of these, miR-200a, is associated with
the potent anticancer effects of a 30% CR diet regimen.
The 8 miRNAs we found from our profiling (specifically, miR-10a, miR-10b, miR-21, miR-
124, miR-125b, miR-126, miR-145, and miR-200a) each showed progressive changes in expres-
sion with advancing lesion grade. The majority of the identified miRNAs are progressively
downregulated from normal expression levels, a finding that is consistent with the general
understanding that miRNAs are globally lost in breast cancers [23]. However, the expression of
miR-21 and miR-200a increased throughout progression, a pattern that suggests these miRNAs
function as oncomiRs in this model. Several of the progression-associated miRNAs identified
mirror those found to be changed during progression in human normal, DCIS, and IDC breast
cancer samples, including an upregulation of miR-21 and a downregulation of miR-10b, miR-
125b, and miR-126 [15]. Further, it is interesting to note in our data that the largest propor-
tional change in miRNA expression consistently occurred between IDP and MIN, suggesting
this transition is a critical window for pro-tumorigenic alterations. Insights such as this are
facilitated by looking at profiles across progression stages, deepening our understanding of the
biology of cancer development and miRNA involvement beyond simply looking at what is
altered between normal tissue and carcinoma.
We and others have demonstrated the strong anticancer effects of CR in multiple rodent
models of mammary cancer, although the effect of CR on luminal mammary tumors, the most
common type of breast cancer in humans, has not been extensively characterized [5,6,24].
Here we found that 30% CR significantly increased tumor-free survival and decreased total size
Fig 2. Eight miRNAs are associated with progression in DMBA-inducedmodel of luminal mammary
cancer.Real-time PCR quantification of the eight miRNAs that showed increasing dysregulation away from
normal expression as tumor progression advanced. Expression of each miRNA at each progression stage is
represented as a fold change relative to expression level in normal tissue, which therefore is at one and is not
shown on the graph. Error bars represent standard error of the mean. *—significant difference from normal tissue
expression, Δ –significant difference from previous lesion grade expression, P<0.05.
doi:10.1371/journal.pone.0159686.g002
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of the tumors that did develop. These findings are in agreement with the few other studies that
have implemented CR in a luminal mammary tumor model, although the model was not char-
acterized as such at the time [25,26,27]. This series of studies led by Kritchevsky and colleagues
found that a range in degrees of CR in different dietary contexts significantly reduced tumor
incidence, multiplicity, and weight, although the molecular mechanisms behind this protective
effect remained largely undefined. Presently, we have shown that the regulation of miR-200a
may be one such mechanism. Of the eight progression-associated miRNAs we identified, miR-
200a was the only one found to be CR-responsive. While expression of this miRNA increased
with advancing cancer progression in rats on the ad libitum Control diet, miR-200a expression
was significantly downregulated in CR tumors compared to Control tumors, indicating that
the CR diet maintains miR-200a expression at levels closer to those seen in normal tissue. Con-
sidering our results to this point, we hypothesized that miR-200a was acting as an oncomiR in
this model and that CR’s normalization of miR-200a could be contributing to the protective
effect of this dietary regimen.
Although the miR-200 family of miRNAs are most traditionally thought of as tumor-sup-
pressive miRNAs because of their ability to target epithelial-to-mesenchymal transition-pro-
moting transcripts, it is clear that miRNAs have many different functions through the targeting
of hundreds of mRNAs, and thus different functions can be dominant in different biological
settings [11,28,29]. MiR-200a is upregulated in many types of cancerous tissue including mam-
mary cancer, and this upregulation can contribute to tumorigenesis by affecting proliferation,
oxidative stress responses, and/or resistance to cell death [30,31,32,33]. Considering our find-
ing that tumors in CR mice were significantly smaller relative to those in Control mice, we
Fig 3. Calorie restriction increases survival and decreases tumor burden relative to control diet. (A), average body weights of
rats within study groups. (B), Percentage of overall survival following DMBA treatment until study endpoint. (C), Average total ex vivo
tumor area of rats treated with DMBA. Error bar indicate standard deviation, P<0.05.
doi:10.1371/journal.pone.0159686.g003
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investigated how CR’s regulation of miR-200a may affect cellular proliferation. When miR-
200a was inhibited in both rat and human luminal mammary cancer cell lines, mimicking CR’s
effect on this miRNA, we found proliferation was significantly reduced. This finding suggests
that CR may reduce tumor burden by dampening cellular proliferation through the prevention
of miR-200a upregulation.
In summary, we have presented, for the first time, a luminal mammary cancer progression-
associated miRNA profile and have shown that CR prevents the dysregulation of one of these
miRNA, miR-200a. Further, we have shown that CR greatly reduces tumor initiation and
growth, a protective effect that can be explained, at least in part, through CR’s normalization of
miR-200a expression and resultant inhibition of cellular proliferation. These findings deepen
our understanding of the dysregulation of miRNA throughout cancer progression and suggest
that miR-200a may be a novel intervention target for mimicking the suppressive effects of CR
on mammary tumor development and growth.
Fig 4. The downregulation of progression-associated miR-200a by CR inhibits cellular proliferation.
(A), Real-time PCR quantification of tumoral miR-200a expression. (B), Luminescence signal following miR-
200a inhibition indicating efficiency of miR-200a targeting. (C), A370 following BrdU incorporation indicating
cellular proliferation. Error bars indicate standard error of the mean, P<0.05.
doi:10.1371/journal.pone.0159686.g004
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